Dr. Thakuri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
551 Brevard Rd
Asheville, NC 28806Phone+1 828-212-7021Fax+1 828-232-8218
Summary
- Dr. Mohan Thakuri is an oncologist in Asheville, NC and is affiliated with multiple hospitals in the area, including Angel Medical Center, Mission Hospital, Transylvania Regional Hospital, and Harris Hospital. He received his medical degree from Tribhuvan University Institute of Medicine and has been in practice 26 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, multiple myeloma, Non-Hodgkin Lymphoma and Hodgkin's lymphoma.
Education & Training
SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000- SUNY Upstate Medical UniversityResidency, Internal Medicine, 1994 - 1997
Tribhuvan University Inst of MedicineClass of 1991
Certifications & Licensure
NC State Medical License 2001 - 2025
IN State Medical License 1998 - 2003- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 597 citationsBortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autolo...Brian G.M. Durie, Antje Hoering, Muneer H. Abidi, S. Vincent Rajkumar, Joshua Epstein
Lancet. 2017-02-04 - 91 citationsLonger term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) wit...Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein
Blood Cancer Journal. 2020-05-11 - 16 citationsPhase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).Alison Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock
Blood Advances. 2021-07-13
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
